Xylem’s $1.5 Billion Authorization Dates to February; No New November Announcement Confirmed
Key Facts
No official announcement confirms a new Xylem share repurchase authorization on November 13, 2026; the $1.5 billion authorization dates to February 25, 2026, according to a company statement. The statement sets a ceiling for purchases, not a new announcement in November. The company’s third-quarter filing showed that $105 million remained available under the program as of September 30. Most of the authorization had therefore been used before the end of that month. The execution places the program in the context of returning capital to shareholders as the company faces pressure on revenue and its full-year outlook.
Xylem said repurchases under the February authorization could take place from time to time in the open market or through privately negotiated transactions. It also said the company could suspend or terminate the program at any time, depending on market conditions and other factors. The statement did not tie that flexibility to a binding timetable for purchasing the full amount. Chief Executive Matthew Pine said the authorization “affirms our confidence in Xylem’s strategy and our ability to generate strong, sustainable cash flows.” The statement reflects the rationale management gave when approving the program in February, while subsequent disclosure figures show how much of it was executed.
In the three months ended September 30, 2026, Xylem repurchased 3.2 million shares for $349 million under the program. For the nine months ended on the same date, the company repurchased a total of 12.2 million shares for $1,396 million. The company said in its filing that $105 million remained available after those transactions. The difference between the value of completed purchases and the ceiling announced in February shows the progress made in using the authorization during the year. These figures show execution through the end of September, not subsequent purchases or a separate November announcement.
The program was executed as the company recorded $2.3 billion in orders in the third quarter, up 7% on a reported basis and 10% organically year over year. Revenue, however, was $2.2 billion, down 3% on a reported basis, while remaining flat organically. Xylem attributed the revenue pressure to project timing and more cautious spending decisions. The company said strong order activity and resilient earnings demonstrated the resilience of its business despite these factors. Pine added that “the resilience we have built, which was evident this quarter, enables us to make those choices deliberately and from a position of strength.”
On October 27, Xylem cut its full-year 2026 revenue outlook to about $8.95 billion, equivalent to a reported decline of 1% year over year, from its previous forecast of 2% reported growth. It also revised its organic revenue outlook to flat, from previous growth guidance of between 2% and 3%. The company lowered its adjusted earnings-per-share guidance range to $5.40–$5.45, from the previous range of $5.55–$5.70. Investing.com reported that the $8.95 billion revenue forecast was below the analyst consensus of $9.19 billion. After the results and outlook update on October 27, the stock fell 4.5% in premarket trading, according to the same source.
Upcoming company changes include reorganizing its businesses into three segments: Treatment and Services, Flow Solutions, and Measurement and Analytics. Xylem said the new structure will take effect on January 1, 2027. It also announced plans to exit its International Applied Water and Specialized Flow Control businesses as part of its portfolio changes. These steps place the share repurchases alongside a broader review of the company’s activities and operating structure. The company said its business resilience enables it to make these choices deliberately and from a position of strength.